1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals

7427.TWO
Great Novel Therapeutics Biotech & MedicalsTW flagTaipei Exchange
49.10
TWD
+3.50
- -
2.11BMarket Cap
Great Novel Therapeutics Biotech & Medicals
7427.TWO
(Taipei Exchange)

Recent

price

49.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.21
0.01
- -
0.02
0.02
0.13
0.04
- -
Revenue per Share
-2.62
-1.78
-1.59
-1.37
-1.92
-1.6
-2.42
- -
Basic EPS, GAAP
-2.46
-3.06
-2.8
-2.37
-2.7
-1.95
-1.85
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1
-1.76
-0.9
-0.52
-0.08
-1.49
-2.51
- -
Book Value per Share
4.52
1.69
3.69
4.59
9
13.25
13.98
- -
Tangible Book Value per Share
14
17
20
26
29
38
43
- -
Basic Weighted Avg Shares
3
- -
- -
1
1
5
2
1
Sales/Revenue/Turnover
-1,299.68
-34,610.23
- -
-5,796.98
-10,636.67
-1,357.11
-6,685.28
-8,260.91
Operating Margin (%)
1
1
1
1
2
4
7
8
Depreciation Expense
-36
-30
-31
-36
-56
-61
-105
-97
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,252.36
-33,948.86
- -
-5,691.59
-10,329.44
-1,257.67
-6,226.94
-8,089.05
Profit Margin (%)
58
23
62
104
239
470
577
447
Working Capital
- -
- -
- -
- -
- -
11
7
4
LT Debt
69
67
121
208
361
534
633
503
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.41%
-20.58%
Free Cash Flow
- -
11.11%
13.37%
Net Income, GAAP
- -
28.9%
-7.1%
Sales/Revenue/Turnover
- -
261.2%
-28.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.6
2024
- -
- -
- -
- -
-2.42
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Awakn Life Sciences Corp. (AWKN.NE)
Akero Therapeutics, Inc. (AKRO)
PreveCeutical Medical Inc. (PREV.CN)
GeNeuro S.A. (GNRO.PA)
Monte Rosa Therapeutics, Inc. (GLUE)
TWi Biotechnology, Inc. (6610.TWO)
Business
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (7427.TWO) develops innovative oral drugs for cancer immunotherapy targeting advanced and refractory cancers, including epigenetic modulators, tumor microenvironment regulators, and immune-regulating multi-kinase inhibitors; core products encompass the licensed oral anti-cancer agent Tucidinostat (trade name Kepida or 剋必達), approved in Taiwan for HR+/HER-2- advanced breast cancer and under review for relapsed/refractory peripheral T-cell lymphoma, alongside proprietary pipeline candidates such as GNTbm-38, an epigenetic immune activator reprogramming the tumor microenvironment to enhance T-cell infiltration and immune memory, and GNTbm-TKI, a multi-tyrosine kinase inhibitor targeting ROS1, BTK, and ATM kinases for synergistic immunotherapy combinations. Founded in 2013 and headquartered at No. 508, Section 7, Zhongxiao East Road, Taipei City, Taiwan, the company operates primarily in the biotechnology sector with a focus on Taiwan, China, the US, and global markets through worldwide patent protections and clinical development strategies emphasizing orphan indications and solid tumors. Recent developments include the commercial launch of Kepida in Taiwan targeting a TWD 35-50 billion market for second-line HR+/HER-2- breast cancer treatment, achievement of national health insurance reimbursement approval for Kepida in November 2025, a manufacturing partnership with Taiyo for GNTbm-38 production to support US, China, and Taiwan IND applications planned for early 2026, preclinical data presentations on GNTbm-38 at the 2025 ASCO Annual Meeting demonstrating superior efficacy in combination with TKIs and PD-1 inhibitors against cold tumors, and on GNTbm-TKI at the 2025 ESMO Annual Meeting highlighting potent immune activation.